Hedwig Blommestein

Associate professor

Erasmus University Rotterdam

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hedwig Blommestein is an Associate Professor at Erasmus University Rotterdam in the Netherlands. Her research areas include health economics, with a focus on cost-effectiveness and utility assessments in oncology treatments, particularly in advanced melanoma and head and neck cancer. She has contributed to the field through various studies analyzing treatment-related toxicity and the economic implications of different treatment sequences for cancer patients.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (6)

Elisabeth de Vries

Professor

Universitair Medisch Centrum Utrecht

NETHERLANDS

View details

S. Zweegman

NETHERLANDS

View details

Brenda Leeneman

Assistant professor

Erasmus Universiteit Rotterdam Erasmus School of Health Policy and Management

NETHERLANDS

View details

Jonas Schreyögg

GERMANY

View details

Frederick Wilhelm Thielen

Assistant professor

Erasmus Universiteit Rotterdam Erasmus School of Health Policy and Management

NETHERLANDS

View details

Meilin Möllenkamp

Universität Hamburg

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hedwig Blommestein

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Cost-benefit analysis of advanced CBCT imaging: Incremental costs and savings

Reply to comment on Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study

Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma

Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model

Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma

Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer

Health‐related quality of life in patients with steroid‐refractory acute graft‐versus‐host disease

Changes in survival in de novo metastatic cancer in an era of new medicines

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands

Treatment sequences and drug costs from diagnosis to death in multiple myeloma

High hospital-related burden of treatment for multiple myeloma patients: outcomes of a feasibility study using reimbursement data from electronic health records

Variation in the utilization of medical devices across Germany, Italy, and the Netherlands: A multilevel approach

Cost-effectiveness: maximizing impact by meticulous data

Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review

Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma

Collaborators (6)

Elisabeth de Vries

S. Zweegman

Brenda Leeneman

Jonas Schreyögg

Frederick Wilhelm Thielen

Meilin Möllenkamp

Make your next move.